BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 7, 2017
View Archived Issues
Roche describes novel HBsAg secretion inhibitors
Read More
Bristol-Myers Squibb presents new TGF-beta receptor type-1 inhibitors
Read More
Eisai reflects on key achievements of third quarter of fiscal 2016
Read More
Novartis initiates phase I trial of HKT-288 in solid tumors
Read More
Reduced SOD1 gene expression as a biomarker in patients with primary glaucoma
Read More
Ariad files for European marketing approval of brigatinib
Read More
FDA approves IND for light-activated drug to treat ocular melanoma
Read More
Researchers announce discovery of first blood biomarker for MS
Read More
Galena reports positive outcome of futility assessment of NeuVax trials
Read More
Sobi announces potential sale of the partner products business area
Read More
In situ activation of platelets enhances anti-PD-L1 delivery and reduces post-surgical recurrence
Read More
Activation of microRNA-1182 may induce melanoma apoptosis
Read More
Exosome Diagnostics and Merck KGaA sign agreement to advance drug development efforts
Read More
First-in-human trial demonstrates efficacy of 68Ga-BBN-RGD for prostate cancer diagnosis and staging
Read More
Sirnaomics initiates first-in-human study of STP-705
Read More
Bayer discloses novel isocitrate dehydrogenase (NADP+) inhibitors
Read More
Institute of Experimental Botany identifies apoptosis inducers/ROS inhibitors
Read More
Following successful phase I testing, CF drug SPX-101 will move to phase II
Read More
FDA lifts partial clinical hold on phase III study of DCVax-L
Read More
Takeda discovers prostanoid EP4 receptor antagonists
Read More
Renova announces development plans for stresscopin
Read More
Enanta patents novel benzodiazepine derivatives
Read More
BioTime acquires ophthalmology assets from University of Pittsburgh
Read More
Isogenica grants license to Maverick Therapeutics for antibody technology
Read More